Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-04-04

Clinical Trial Update: Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of bexarotene and interferon alfa for cutaneous T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bexarotene (Bexarotene)
  • Interferon Alfa (interferon alfa)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED